CAPR
CAPRICOR THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$6.63
+6.42%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +1792.0%
- EBIT
- -84.1%
- EPS
- -49.4%
- Free cash flow
- —
- Operating cash flow
- -96.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -23.3%
- EPS
- +27.3%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- -96.5%
- Free cash flow
- -75.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026